Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Aurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 16 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of five analysts for the quarter was for earnings of 10 cents per share. Wall Street expected results to range from 7 cents to 14 cents per share.

• Revenue rose 24.2% to $62.47 million from a year ago; analysts expected $61.54 million.

• Aurinia Pharmaceuticals Inc's reported EPS for the quarter was 16 cents​.

• The company reported quarterly net income of $23.34 million.

• Aurinia Pharmaceuticals Inc shares had fallen by 0.5% this quarter and lost 10.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.43

This summary was machine generated from LSEG data May 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)